Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ovid Therapeutics Inc OVID

Healthcare Biotechnology
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other... see more

Recent & Breaking News (NDAQ:OVID)

Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress

GlobeNewswire November 9, 2017

Ovid Therapeutics to Participate at the Stifel 2017 Healthcare Conference

GlobeNewswire November 8, 2017

Ovid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome Model

GlobeNewswire October 16, 2017

Ovid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for Treatment of Fragile X Syndrome

GlobeNewswire October 10, 2017

Ovid Therapeutics to Present Preclinical Data Demonstrating OV101 Normalizes Behavioral Abnormalities at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop

GlobeNewswire October 5, 2017

Ovid Therapeutics Appoints Ana C. Ward as Senior Vice President and General Counsel

GlobeNewswire September 6, 2017

Ovid Therapeutics Announces First Patient Randomized in Phase 1b/2a Clinical Trial of TAK-935/OV935 in Adults with Rare Epilepsies

GlobeNewswire August 21, 2017

Ovid Therapeutics to be Added to Russell 2000®, 3000® and Microcap® Indexes

GlobeNewswire June 23, 2017

Ovid Therapeutics Appoints Barbara G. Duncan to its Board of Directors

GlobeNewswire June 14, 2017

Ovid Therapeutics Reports First Quarter 2017 Financial Results and Recent Corporate Progress

GlobeNewswire June 13, 2017

Ovid Therapeutics to Participate in the JMP Securities 2017 Life Sciences Conference

GlobeNewswire June 12, 2017

For Rare Neural Diseases, Is Ovid Therapeutics The Right Team At The Right Time?

Benzinga.com  May 30, 2017

10 Biggest Mid-Day Losers For Tuesday

Benzinga.com  May 30, 2017

Ovid Therapeutics to Present Preclinical Data on TAK-935/OV935 at the Antiepileptic Drug and Device Trials XIV Conference

GlobeNewswire May 12, 2017

Ovid Therapeutics Inc. (Nasdaq: OVID) to Ring The Nasdaq Stock Market Closing Bell

GlobeNewswire May 9, 2017

Ovid Therapeutics Announces Pricing of Initial Public Offering

GlobeNewswire May 4, 2017